Targovax presents further positive clinical data from TG01 phase I/II trial at 2017 ASCO annual meeting
June 06, 2017 01:03 ET
|
Targovax ASA
Oslo, Norway, 6 June 2017: Targovax ASA ("Targovax" or "the Company"; OSE: TRVX), a clinical stage company focused on developing immuno-oncology therapies to target treatment-resistant solid tumors,...
Targovax announces formal agenda for 2017 Capital Markets Updates in Oslo and London
June 06, 2017 01:02 ET
|
Targovax ASA
Oslo, Norway, 6 June 2017 - Targovax ASA ("Targovax" or "the Company"; OSE: TRVX), a clinical stage company focused on developing immuno-oncology therapies to target solid tumors, announces formal...
Targovax ASA: ASCO abstract released
May 18, 2017 01:03 ET
|
Targovax ASA
Oslo, Norway, 18 May 2017: Targovax ASA ("Targovax" or "the Company"; OSE: TRVX), a clinical stage company focused on developing immuno-oncology therapies to target treatment-resistant solid tumors,...
Targovax recruits first patient into first ONCOS-102 /Checkpoint inhibitor melanoma study
May 10, 2017 02:06 ET
|
Targovax ASA
Proof of concept study of sequential ONCOS-102 then pembrolizumab treatment in patients with advanced melanoma refractory to check-point inhibitors Oslo 10 May 2017: Targovax ASA ("Targovax" or...
Targovax ASA: Capital Markets Updates in Oslo on Thursday 8 June and in London on Monday 26 June 2017
May 08, 2017 01:01 ET
|
Targovax ASA
Oslo, Norway, 8 May 2017 - Targovax ASA ("Targovax" or "the Company"; OSE: TRVX), a clinical stage company focused on developing immuno-oncology therapies to target solid tumors, will be hosting...
Targovax ASA: Issuance of restricted stock unites (RSUs) to the board members
April 28, 2017 06:34 ET
|
Targovax ASA
Reference is made to annual general meeting of Targovax ASA's (the "Company") on 5 April 2017 (the "AGM") where all the board members were re-elected. At the annual general meeting of the Company the...
Targovax ASA: First quarter 2017 results
April 25, 2017 01:01 ET
|
Targovax ASA
Oslo, Norway, 25 April 2017 - Targovax ASA ("Targovax" or "the Company"; OSE: TRVX), a clinical stage company focused on developing immuno-oncology therapies to target solid tumors, today announces...
Targovax initiates first clinical trial with TG02, the second product from its RAS-peptide immunotherapy platform
April 20, 2017 01:01 ET
|
Targovax ASA
First patient enrolled in a Phase Ib trial in patients with locally recurrent RAS-mutated rectal cancer Oslo, 20 April 2017: Targovax ASA ("Targovax" or "the Company"; OSE: TRVX), a clinical...
Targovax ASA: Invitation to first quarter 2017 results presentation Tuesday 25 April
April 19, 2017 01:01 ET
|
Targovax ASA
Oslo, Norway, 19 April 2017 - Targovax ASA (OSE: TRVX), a clinical stage company focused on developing immuno-oncology therapies to target solid tumors, will announce its first quarter 2017 results...
Targovax to present clinical data on its phase I/II clinical trial evaluating TG01 in resected pancreatic cancer at the ASCO Annual Meeting
April 06, 2017 01:01 ET
|
Targovax ASA
Oslo, Norway, 6 April 2017: Targovax ASA ("Targovax" or "the Company"; OSE: TRVX), a clinical stage company focused on developing immuno-oncology therapies to target treatment-resistant solid tumors,...